

ANTICOAGULATION Documentation and Results Reviewing Uplift

Anticoagulation documentation has been revised to support an improved, trendable result viewing experience for clinicians.

The following PowerForms will be retired and will not be available in the Ad Hoc Charting folder:

- Anticoagulation Workflow
- Anticoagulation Therapy Management

A new PowerForm will be Available in the Ad Hoc Charting folders for documenting anticoagulation management

• Anticoagulation Therapy

P Anticoagulatio	Therapy - ZZTEST, MEDICARE		
🖌 🖻 🚫 淡	👫 🛧 🖊 💷 🔛 🗎		
*Performed on:	12/13/2018 🔹 💌 1011 🚔 EST	T By: Cerner	Test, Physician - Primary Care Cerner
Overview Warfarin	Anticoagulation Ov	rerview	<u>^</u>
Other Anticoagula	Type of Visit	Current Anticoagulant Treatment Start Date History of HIT	Date of HIT
Bridge Therapy	O Anticoagulation Clinic	O Warfarin (Cournadin) © /∞/∞ /∞ ♥ ● O Yes O No No	
	Indication of Anticoagulation		
	Abnormal Lupus Anticoagulant assay Abnormal anti-beta-2-glycoprotein-1 Ig0 Antiphospholid Antibody Antiphospholid Antibody Syndrome Antibrhombin III Deficiency Aortic Mechanical Valve Replacement Atrial fibrillation Atrial fibrillation Atrial Septal Defect Bioprosthetic heart valve Cardiac Homograft Valve Prosthesis Cardioembolic Stroke Cardiomyopathy	Elevated Homocysteine Factor V Leiden Thrombophilia Transient Ischemic Attack Mitral Mechanical Valve Replacement Valvular Heart Disease	
	4	117	
			In Progress





	ZTEST, MEDICARE					×
🖉 💥 🔟						
Warfari	in					
INR Outside		D	ose Update Contac	t	Next Scheduled INR	
	O 2.0 (1.5-2.5 PAH)		Patient		ж/ж/жж	
Reference	2.5 (2.0-3.0) 3.0 (2.5-3.5)) Spouse) Care Giver			
Range 0.9 - 1.1	O Other:		Guardian			
0.9 - 1.1						
		L				
INR POC	Quality Control	Pe	erformed Date & Tir	ne		
	O Pass O Fail	NN		A V		
Reference	2					
Range 0.9 - 1.1	Performed By:					E
	Dorformed Location					
	Performed Location					
Dose Inform	ation					
Current Pill	Strengths		Bridge Dosing	Needed		
🗌 1 mg	☐ 3 mg ☐ 6 mg		O Yes			
☐ 2 mg ☐ 2.5 mg	☐ 4 mg ☐ 7.5 mg ☐ 5 mg ☐ 10 mg					
2.5 mg						
Dose Sched						
O Continue do	ose schedule 🔿 New dose schedule					
	Sunday Monday	Tuesday Wednes	sday Thursday	Friday S	aturday	
Dose mg						
y				I		1
	Progress Notes					
	Segoe UI 👻 9	- 🤫 🕺 🖿 🗊	B U <i>I</i> S ≣	ΞΞ		
	4					
						In Progress
Po	ther Anticoagulant - ZZTEST, MEDICARE					
U	× 🔟					
O	ther Anticoagulant M	edication				
	ner Anticoagulant	Apixaban	Dabigatran	Rivaroxaban Non	Rivaroxaban	
	Apixaban	O 2.5 mg PO bid	O 75 mg PO bid	Valvular Afib	DVT,PE Treatment	
0	dabigatran Rivaroxaban non valvular Afib treatment	O 5 mg PO bid	O 150 mg PO bid	O 20 mg PO daily	O 20 mg PO daily	
	Rivaroxaban non vaivular Arib treatment Rivaroxaban DVT, PE treatment					E
	evant Lab Value	Communication		1		
00						





Image: Second Secon	P Bridge Therapy - ZZTEST, MEDICARE	×
Bridging Medication Enswspain [Lovernox] Fondaparinux [Aikita] Other Therapeutic Bridge Dosing Options: Enoxaparin (Lovenox) Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 60mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 60mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 150mg/0.3mL SQ QD Enoxaparin 40mg/0.3mL SQ Q12H Enoxaparin 80mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Enoxaparin 40mg/0.3mL SQ Q12H Enoxaparin 80mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Other Fondaparinux (Arixtra) Other Bridging Medication Enoxaparin 20mg/0.3mL SQ Q12H Other Bridging Medication Fondaparinux 10mg subQ daily Other Enoxaparin 20mg subQ daily Enoxaparin 20mg/0.3mL SQ Q12H Enoxaparin 20mg/0.3mL SQ Q12H Other: Differ Bridging Medication Enoxaparin 20mg subQ daily Enoxaparin 20mg subQ subQ subQ subQ subQ subQ subQ s	U 🖉 🖬	
Bridging Medication Enswspain [Lovernox] Fondaparinux [Aikita] Other Therapeutic Bridge Dosing Options: Enoxaparin (Lovenox) Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 60mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 60mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 150mg/0.3mL SQ QD Enoxaparin 40mg/0.3mL SQ Q12H Enoxaparin 80mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Enoxaparin 40mg/0.3mL SQ Q12H Enoxaparin 80mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Other Fondaparinux (Arixtra) Other Bridging Medication Enoxaparin 20mg/0.3mL SQ Q12H Other Bridging Medication Fondaparinux 10mg subQ daily Other Enoxaparin 20mg subQ daily Enoxaparin 20mg/0.3mL SQ Q12H Enoxaparin 20mg/0.3mL SQ Q12H Other: Differ Bridging Medication Enoxaparin 20mg subQ daily Enoxaparin 20mg subQ subQ subQ subQ subQ subQ subQ s	Bridge Therapy	*
Enoxaparin (Lovernov) Fondaparinux (Aristra) O Uther Therapeutic Bridge Dosing Options: Enoxaparin (Lovenox) Enoxaparin 30mg/0.3mL SQ 0D Enoxaparin 60mg/0.3mL SQ 0D Enoxaparin 100mg/0.3mL SQ 0D Enoxaparin 100mg/0.3mL SQ 0D Enoxaparin 40mg/0.3mL SQ 012H Enoxaparin 60mg/0.3mL SQ 012H Enoxaparin 100mg/0.3mL SQ 012H Enoxaparin 100mg/0.3mL SQ 012H Enoxaparin 40mg/0.3mL SQ 012H Enoxaparin 80mg/0.3mL SQ 012H Enoxaparin 120mg/0.3mL SQ 012H O Uther: Fondaparinux (Arixtra) Other Bridging Medication Enoxaparin 20mg/0.3mL SQ 012H Enoxaparin 20mg/0.3mL SQ 012H Fondaparinux 10mg subQ daily Other Bridging Medication Enoxaparin 20mg/0.3mL SQ 012H Enoxaparin 20mg/0.3mL SQ 012H Dosing Comments Enoxaparin 20mg subQ daily Other Enoxaparin 20mg/0.3mL SQ 012H Enoxaparin 20mg/0.3mL SQ 012H		- 11
Enoxaparin (Lovenox) Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 60mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Enoxaparin 150mg/0.3mL SQ QD Enoxaparin 30mg/0.3mL SQ Q12H Enoxaparin 60mg/0.3mL SQ Q12H Enoxaparin 100mg/0.3mL SQ Q12H Enoxaparin 100mg/0.3mL SQ Q12H Enoxaparin 40mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Enoxaparin 120mg/0.3mL SQ Q12H Other: Fondaparinux (Arixtra) Other Bridging Medication Enoxaparin 120mg/0.3mL SQ Q12H Other Bridging Medication Fondaparinux 10mg subQ daily Fondaparinux 10mg subQ daily Enoxaparin 10mg subQ daily Enoxaparin 10mg subQ daily Other: Dosing Comments Enoxaparin 20mg subQ daily Enoxaparin 20mg subQ daily		
Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 60mg/0.3mL SQ QD Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 30mg/0.3mL SQ QD Enoxaparin 40mg/0.3mL SQ QD Enoxaparin 80mg/0.3mL SQ QD Enoxaparin 100mg/0.3mL SQ QD Other	Therapeutic Bridge Dosing Options:	
Enoxaparin 30mg/0.3mL SQ 012H Enoxaparin 60mg/0.3mL SQ 012H Enoxaparin 100mg/0.3mL SQ 012H Enoxaparin 100mg/0.3mL SQ 012H Enoxaparin 100mg/0.3mL SQ 012H Enoxaparin 40mg/0.3mL SQ 012H Enoxaparin 80mg/0.3mL SQ 012H Enoxaparin 120mg/0.3mL SQ 012H Enoxaparin 120mg/0.3mL SQ 012H Other: Fondaparinux (Arixtra) Other Bridging Medication Fondaparinux 75mg subQ daily Fondaparinux 10mg subQ daily Other: Enoxaparin 20mg subQ daily Other: Dosing Comments Enoxaparin Enoxaparinux Enoxaparinux	Enoxaparin (Lovenox)	
O Fondaparinus 5mg subQ daily Fondaparinus 75mg subQ daily O Fondaparinus 10mg subQ daily O O Other: D Dosing Comments D D	C Enoxaparin 30mg/0.3mL SQ Q12H C Enoxaparin 60mg/0.3mL SQ Q12H C Enoxaparin 100mg/0.3mL SQ Q12H C Enoxaparin 150mg/0.3mL SQ Q12H C Enoxaparin 100mg/0.3mL SQ Q12H C	
-	Fondaparinux 5mg subQ daily Fondaparinux 7.5mg subQ daily Fondaparinux 10mg subQ daily	
· · · · · · · · · · · · · · · · · · ·		

The PowerForm has been designed to facilitate documentation by using "last charted value" functionality to pull previously documented information into every new instance of the form. After the form has been completed for the first-time future charting is minimal.

Note the following:

- INR
 - Results that post to PowerChart via interface will be viewable in the new "Coumadin Flowsheet" section in Results Review located in the TOC on the left.
- INR Outside
 - o Allows the nurse or MA to enter a result from a non-interfaced lab system
- INR POC
 - \circ $\;$ Is only for those clinics that perform INR testing in the Clinic.
 - When this question is answered the Quality Assurance questions will also need to be completed.

DOING WHAT'S BEST.


 \circ $\;$ When the form is signed A CHARGE WILL DROP for the INR POC test.





Clinicians will be able to view and trend the information documented from the Results Review Tab.

ecent Results Ambulatory Vie	w Lab - Recent Lab - Extended Path	ology Microbiology	Imaging Vitals - Recent	Vitals - Extended	Assessments - Provider View	Cardiology	
Flowsheet: Ambulatory View	▼ Level: Ambul	latory View	▼	ıp 🔘 List			
			Last 10	0 Results in the Pa	st 1 Years		
Navigator 🛛 🔀	Showing results from (11/28/18 - 12/13/1	18) Show more results					
Measurements	Ambulatory View	12/05/18 11:06 E	ST 12/03/18 17:35 EST	12/03/18 12:51 E	ST 11/29/18 19:44 EST	11/29/18 17:11 EST	11/2
Vital Signs	Coumadin Flowsheet Visit Type	Anticoagulation Cli	nic Anticoagulation Clinic				
Coumadin Flowsheet	Indication for Anticoagulation Treatment Start Date	Aortic Mechanical V 10/29/17	alve Aortic Mechanical Valve 10/29/17	1		Aortic Mechanical Valve I 10/29/17	
🗾 Daily Doses	Hx of HIT	Yes	Yes			Yes	
Bridging Medications	Hx of HIT Date Coumadin Progress Note	11/08/18	11/08/18 Anticoag - Warfarin Pro	c		11/08/18 Anticoag - Warfarin Prog	
	INR Level POC	3.5	Anticoug - Mananin To	2		2.5	
Routine Chemistry	Target INR Pill Strength	2.5 (2.0-3.0) 1 mg, 2 mg	2.5 (2.0-3.0) 1 mg, 2 mg			2.5 (2.0-3.0) 1 mg (Pink), 2 mg (Laveno	
Office/Clinic Notes	Dose Schedule	1	Continue dose schedule	2		New dose schedule	
Correspondence	Daily Doses					-	
PowerForm Textual Rendition	Sunday Dose mg Monday Dose mg	1	1			2	
🕱 Bridging	Tuesday Dose mg Wednesday Dose mg	1	1			2	
	Thursday Dose mg	2	2			1	
	Friday Dose mg	2	2			1	
	Saturday Dose mg	1	1			2	
	Bridging Medications						







WORKFLOW

In Family Practice Clinics:

- 1. Interfaced INR results will Post to PowerChart and route a result message to the doctor's Message Center.
- 2. Doctor will review the result in Message Center
- 3. From Message Center physicians can click the Summary View button to review the documentation on the Anticoagulation Therapy PowerForm.
- 4. Physician will use their preferred method to communicate with the nurse or MA and give them the instructions to give to the patient.
- 5. Nurse or MA will document any changes, etc. in the PowerForm.

In Cardiology Clinics:

- Physicians are always free to use the workflow process described above.
- 1. Maintain current state workflow for tracking patients and results
- 2. PA -C or Nurse document contact with Patient using the Anticoagulation PowerForm

***** A specific workflow design is in process, but it was felt that the need for this new documentation with the supported results review needs to be pushed out as soon as possible for patient safety reasons.





A second PowerForm will also be available to document anticoagulation bridging medications

• Anticoagulation Bridge Medications

Image: Second
Bridging Medication O Enoxaparin (Lovenox) O Fondaparinux (Aristra) O Ither
C Eroxaparin (Lovenox) C Fondaparinux (Aristra) C Other Therapeutic Bridge Dosing Options:
Therapeutic Bridge Dosing Options:
Enoxaparin (Lovenox)
C Enoxaparin 30mg/0.3mL SQ QD C Enoxaparin 60mg/0.3mL SQ QD C Enoxaparin 30mg/0.3mL SQ QD C Enoxaparin 40mg/0.3mL SQ QD
Fondaparinux (Arixtra) Other Bridging Medication
Fondaparinux Sing subQ daily Fondaparinux 7.5mg subQ daily Fondaparinux 10mg subQ daily Other:
Dosing Comments
Segoe UI • 9 • 🍪 🌡 🛍 🛍 🖪 🙂 Z 😙 副 🧮 🗄 🖉

This form is provided as a convenience by provider request for physicians that don't routinely follow their patients for coagulopathy, e.g. surgeons.

